You are here

  • Home
  • Archive
  • Volume 74, Issue Suppl 2
  • AB0842 Gastrointestinal Safety and Tolerability of Long-Term GCSB-5 of Dried Extracts of Six Herbs in Patients with Osteoarthritis: A 24 Weeks, Multi-Centers, Single Arm Phase IV Study

Article Text

Article menu
Download PDFPDF
Abstracts Accepted for Publication
Osteoarthritis
AB0842 Gastrointestinal Safety and Tolerability of Long-Term GCSB-5 of Dried Extracts of Six Herbs in Patients with Osteoarthritis: A 24 Weeks, Multi-Centers, Single Arm Phase IV Study
  1. Y.-B. Park1,
  2. C.-W. Ha1,
  3. H.-S. Kyung2,
  4. H.-C. Lim3,
  5. S.-E. Park4,
  6. H.-C. Kim5,
  7. M.-C. Lee6,
  8. Y.-Y. Won7,
  9. C.-W. Kim8,
  10. J.-G. Kim9,
  11. J.-S. Kang10,
  12. J.-K. Seon11,
  13. S.-I. Bin12
  1. 1Department of Orthopedic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
  2. 2Department of Orthopedic Surgery, School of Medicine, Kyungpook National University, Daegu
  3. 3Department of Orthopedic Surgery, Guro Hospital, Korea University Medical Center, Seoul
  4. 4Department of Orthopedic Surgery, Dongguk University International Hospital, Goyang
  5. 5Department of Orthopedic Surgery, Cha University Bundang Hospital, Seongnam
  6. 6Department of Orthopedic Surgery, Seoul National University Hospital, Seoul
  7. 7Department of Orthopedic Surgery, Ajou University Hospital, Suwon
  8. 8Department of Orthopedic Surgery, Busan Paik Hospital, Inje University, Busan
  9. 9Department of Orthopedic Surgery, Seoul Paik Hospital, Inje University, Seoul
  10. 10Department of Orthopedic Surgery, Inha University Hospital, Incheon
  11. 11Department of Orthopedic Surgery, Chonnam National University Hwasun Hospital, Hwasun-gun
  12. 12Department of Orthopedic Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic Of

Abstract

Background A previous study on GCSB-5 showed non-inferiority to Celecoxib in efficacy and safety in treating osteoarthritis, but its safety information on the gastrointestinal (GI) safety was limited to only 12 weeks. A longer term (24 weeks) study with a larger number of patients is necessary to establish the GI safety of GCSB-5.

Objectives The primary goal of this study was to determine the incidence of GI disorders associated with GCSB-5. The secondary goal was to collect the GI safety data of GCSB-5 and compare them with the safety data of the previously reported Celecoxib Long-term Arthritis Safety Study (CLASS).

Methods A single arm safety study of 24-week GCSB-5 for osteoarthritis patients was conducted. Then, the results of GI safety in this study were compared with those from the CLASS. This study was performed in 19 academic institutions between May 2012 and June 2013. Two GCSB-5 capsules (300 mg per capsule) were prescribed two times per day for 24 weeks. A total of 761 patients with osteoarthritis were enrolled and 756 patients took at least one dose of study drug. A total of 629 patients (82.7%) completed the 24 weeks follow-up visit. Incidence of GI disorders was the primary outcome. Incidence of GI perforation, ulcer obstruction and bleeding (PUB), and dropout due to GI complications were the major secondary outcome variables. All the suspected PUB events were forwarded to the GI event committee (GEC), consisted of GI specialist independent of investigators, for PUB diagnosis, treatment and related tests.

Results The incidence of GI disorders was 23.7%. Concomitant Aspirin use did not show any significant difference in GI disorders in this study cohort. The annualized incidence rate of PUB was 0.0%. The drop-out rate due to GI disorders in GCSB-5 was 4.8%. In comparison with CLASS, GCSB-5 was significantly lower in the incidence of GI disorders (23.7% vs 31.4%, p<0.001), annualized rate of PUB and gastroduodenal ulcer (0.0% vs 2.2%, p=0.004), and drop-out rate (4.8% vs 8.7%, p<0.001) due to GI disorders.

Conclusions This study indicated GCSB-5 was safe for osteoarthritis patients during long-term treatment. Furthermore, the safety results of GCSB-5 associated with GI disorder were comparable to Celecoxib.

Acknowledgements This study was supported by Green Cross Corporation, South Korea.

Disclosure of Interest None declared

https://doi.org/10.1136/annrheumdis-2015-eular.3514

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.